Verekitug

韦瑞奇塔单抗

Report date: 2026/04/03 20:03:44

Base Information

Drug NameVerekitug
Drug Alias NameASP-7266UPB-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCytokine receptor-like factor 2 antagonists
TargetsCytokine receptor-like factor 2
Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Pulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[30] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesUpstream Biosciences Inc
Inactive CompaniesAstellas Pharma Inc
Active IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Pulmonary Disease, Chronic ObstructiveAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A